No. Cabo hasn't been studied in many chemo naive patients like in 427 trial where many patients don't even have measurable disease. So it is difficult to make cross trial comparison. Just look at the trial population in 427 trial where many patients responded to control arm prednisone by various measures. Cabo trial are 100% chemo treated, 35% also X/Z treated, 25% also cabazitaxel treated, much sicker population than any other trial with reported data. In addition, RECIST by itself isn't as good a measure in CRPC.
Market Data 
Markets 
AI
